Association between antihypertensive medication and the risk of urinary tract infection (UTI) of outpatients: a retrospective cohort study.
Male
Humans
Female
Antihypertensive Agents
/ therapeutic use
Retrospective Studies
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Hypertension
/ drug therapy
Angiotensin Receptor Antagonists
/ therapeutic use
Outpatients
Adrenergic beta-Antagonists
/ therapeutic use
Calcium Channel Blockers
/ therapeutic use
Diuretics
/ therapeutic use
Antibiotic therapy
Antihypertensive medication
Arterial hypertension (AH)
Pharmacological side effects
Urinary tract infections (UTI)
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
04
2022
accepted:
22
07
2022
medline:
29
3
2023
pubmed:
30
7
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
The aim of this retrospective study was to investigate the impact of a broad spectrum of antihypertensive (AH) medications on urinary tract infections (UTI) of outpatients diagnosed in general practices in Germany. This study included a total of 367,960 patients aged ≥ 18 years newly a diagnosed with UTI in 1274 general practices in Germany between January 2010 and December 2019. The analysis was conducted for five groups representing five AH therapy classes (diuretics (DIU); beta blockers (BB); calcium channel blockers (CCB); ACE inhibitors (ACEi); angiotensin II receptor blockers (ARB)), each containing 73,592 patients. A Cox regression model was used to analyze the association between each antihypertensive drug class and UTI incidence as compared to all other antihypertensive drug classes (as a group). The incidence of UTI diagnosis was slightly higher in patients treated with DIU (8.6%), followed by ACEi (8.1%), ARB (7.9%), and CCB (6.5%). Antibiotic therapy for UTI was given in 5.6% of DIU and 4.3% of CCB patients. The incidence of UTI and antibiotic therapy was much higher in women than in men across all therapy classes. No significant increase or decrease in UTI incidence or antibiotic therapy was observed in any of the AH therapy classes investigated. The present study did not identify a significant increase or decrease of UTI incidence or antibiotic therapy in patients treated with ACEi, ACB, CCB, beta blockers or diuretics. Across all AH classes studied, the incidence of UTI and antibiotic therapy was higher in women than in men, although not significantly.
Identifiants
pubmed: 35906337
doi: 10.1007/s15010-022-01895-8
pii: 10.1007/s15010-022-01895-8
pmc: PMC10042971
doi:
Substances chimiques
Antihypertensive Agents
0
Angiotensin-Converting Enzyme Inhibitors
0
Angiotensin Receptor Antagonists
0
Adrenergic beta-Antagonists
0
Calcium Channel Blockers
0
Diuretics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-424Informations de copyright
© 2022. The Author(s).
Références
J Antimicrob Chemother. 2013 Mar;68(3):708-14
pubmed: 23111852
Drug Saf. 2013 Nov;36(11):1079-86
pubmed: 23832709
Ther Adv Urol. 2019 May 02;11:1756287219832172
pubmed: 31105774
Cell. 2001 Feb 23;104(4):545-56
pubmed: 11239411
Eur J Heart Fail. 2005 Oct;7(6):1049-56
pubmed: 16227143
Nat Rev Endocrinol. 2015 Apr;11(4):242-52
pubmed: 25666495
Circ Res. 2019 Mar 29;124(7):1045-1060
pubmed: 30920928
Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26
pubmed: 19825325
Am J Cardiol. 2000 Sep 15;86(6):635-8
pubmed: 10980214
PLoS One. 2012;7(12):e51860
pubmed: 23251643
Nat Rev Urol. 2010 Dec;7(12):653-60
pubmed: 21139641
Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):865-74
pubmed: 26132313
Kidney Int. 2018 Nov;94(5):993-1001
pubmed: 30274681
BMJ Open. 2019 May 19;9(5):e027221
pubmed: 31110099
J Clin Hypertens (Greenwich). 2021 May;23(5):915-922
pubmed: 33650776
Eur J Clin Nutr. 2003 Dec;57 Suppl 2:S52-8
pubmed: 14681714
Ann Epidemiol. 2000 Nov;10(8):509-15
pubmed: 11118930
Epidemiology. 2014 May;25(3):466-7
pubmed: 24713884
Neurology. 2016 Aug 2;87(5):466-72
pubmed: 27371490
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Circulation. 2004 Nov 2;110(18):2809-16
pubmed: 15492322
Diabetes Obes Metab. 2016 Aug;18(8):840-3
pubmed: 27062643
Clin Epidemiol. 2018 Jan 30;10:187-202
pubmed: 29430198
Epilepsy Behav. 2021 Feb;115:107502
pubmed: 33323337
Lancet. 2015 Dec 5;386(10010):2287-323
pubmed: 26364544
Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):378-83
pubmed: 17929333
Nat Rev Cardiol. 2021 Nov;18(11):785-802
pubmed: 34050340
Biomed Pharmacother. 2017 Oct;94:317-325
pubmed: 28772209
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
Circulation. 2001 Oct 16;104(16):1985-91
pubmed: 11602506
BMC Health Serv Res. 2016 Aug 09;16(a):365
pubmed: 27507292
Vital Health Stat 13. 2006 Feb;(159):1-66
pubmed: 16471269
Hypertension. 2018 Sep;72(3):537-548
pubmed: 29987104
Postgrad Med. 2011 May;123(3):133-43
pubmed: 21566423
Int J Clin Pharmacol Ther. 2022 Apr;60(4):167-175
pubmed: 35006073
Nat Rev Dis Primers. 2018 Mar 22;4:18014
pubmed: 29565029
BMJ. 2021 Feb 10;372:n189
pubmed: 33568342
Br J Gen Pract. 2020 Apr 30;70(694):e330-e338
pubmed: 32041765
J Am Soc Hypertens. 2014 Jul;8(7):519-24
pubmed: 25064774
Infection. 2007 Jun;35(3):150-3
pubmed: 17565455
Int J Clin Pharmacol Ther. 2018 Apr;56(4):162-168
pubmed: 29393847
Int J Clin Pharmacol Ther. 2019 Oct;57(10):483-488
pubmed: 31426904